当前期刊: Gut Go to current issue    加入关注   
显示样式:        排序: 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Reduction of HbA1c in patients with type 2 diabetes following duodenal mucosal resurfacing: could other factors be at play?
    Gut (IF 17.943) Pub Date : 2020-02-26
    Michael P Johnston; Ryan Malcolm Buchanan; Janisha Patel; Nadeem Tehami

    We were interested to read the recent article by van Baar and colleagues that described an open-label phase II trial of endoscopic duodenal mucosal resurfacing (DMR) in the management of patients with type 2 diabetes mellitus (T2DM).1 van Baar and colleagues demonstrated improvements in a number of parameters, most impressive of which was the reduction in haemoglobin A1c (HbA1c) at 12 months. It is

    更新日期:2020-02-27
  • Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus
    Gut (IF 17.943) Pub Date : 2020-02-26
    Weicheng Liang; Zhijie Feng; Shitao Rao; Cuicui Xiao; Xingyang Xue; Zexiao Lin; Qi Zhang; Wei Qi

    A series of pneumonia cases caused by 2019 novel coronavirus (2019-nCoV, also named COVID-19) are being reported globally. Based on recent publications,1–3 the most common symptoms in patients infected by 2019-nCoV were fever and cough. However, the incidence of other clinical features differs in different reports. To address this issue, we collected the data from three reports1–3 and compared the

    更新日期:2020-02-27
  • Albumin in decompensated cirrhosis: new concepts and perspectives
    Gut (IF 17.943) Pub Date : 2020-02-26
    Mauro Bernardi; Paolo Angeli; Joan Claria; Richard Moreau; Pere Gines; Rajiv Jalan; Paolo Caraceni; Javier Fernandez; Alexander L Gerbes; Alastair J O'Brien; Jonel Trebicka; Thierry Thevenot; Vicente Arroyo

    The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory

    更新日期:2020-02-27
  • Faecal microbial transplantation in IBS: ready for prime time?
    Gut (IF 17.943) Pub Date : 2020-02-26
    Giovanni Barbara; Gianluca Ianiro

    The urge of deciphering the secrets of gut microbiota has pervaded merely all fields of medicine, including that of functional GI disorders, now called disorders of gut brain interaction (DGBI).1 The concept that gut microbiota could contribute to symptom generation in DGBI, particularly in IBS is not new. Dysbiosis, small intestinal bacterial overgrowth and bacterial fermentation of foods have been

    更新日期:2020-02-27
  • Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device
    Gut (IF 17.943) Pub Date : 2020-02-25
    Yonne Peters; Ruud W M Schrauwen; Adriaan C Tan; Sanne K Bogers; Bart de Jong; Peter D Siersema

    Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett’s oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds

    更新日期:2020-02-26
  • New role for azathioprine in case of switching anti-TNFs in IBD
    Gut (IF 17.943) Pub Date : 2020-02-19
    Konstantinos Papamichael; Adam S Cheifetz; Peter M Irving

    Antitumour necrosis factor (anti-TNF) therapy has revolutionised the treatment of moderate to severe inflammatory bowel disease (IBD). However, up to 30% of patients with Crohn’s disease (CD) and ulcerative colitis (UC) do not respond to anti-TNF therapy, often referred to as primary non-responders. Additionally, almost 50% of patients who initially respond to anti-TNF lose response over time, a phenomenon

    更新日期:2020-02-19
  • Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake
    Gut (IF 17.943) Pub Date : 2020-02-19
    Victoria Meslier; Manolo Laiola; Henrik Munch Roager; Francesca De Filippis; Hugo Roume; Benoit Quinquis; Rosalba Giacco; Ilario Mennella; Rosalia Ferracane; Nicolas Pons; Edoardo Pasolli; Angela Rivellese; Lars Ove Dragsted; Paola Vitaglione; Stanislav Dusko Ehrlich; Danilo Ercolini

    Objectives This study aimed to explore the effects of an isocaloric Mediterranean diet (MD) intervention on metabolic health, gut microbiome and systemic metabolome in subjects with lifestyle risk factors for metabolic disease. Design Eighty-two healthy overweight and obese subjects with a habitually low intake of fruit and vegetables and a sedentary lifestyle participated in a parallel 8-week randomised

    更新日期:2020-02-19
  • When entomology meets gastroenterology
    Gut (IF 17.943) Pub Date : 2020-02-19
    Grigoriy E Gurvits; Rashelle Tsyrlin

    A middle age man with coronary artery disease requiring recent percutaneous angioplasty with drug eluding stent was seen for evaluation of new onset iron deficiency anaemia. His medical history was remarkable for peptic ulcer disease as young adult requiring Billroth II resection. His current medications included aspirin 81 mg daily and prasugrel 10 mg daily. Laboratory analysis was notable for haemoglobin

    更新日期:2020-02-19
  • Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries
    Gut (IF 17.943) Pub Date : 2020-02-17
    Tarini Shankar Ghosh; Simone Rampelli; Ian B Jeffery; Aurelia Santoro; Marta Neto; Miriam Capri; Enrico Giampieri; Amy Jennings; Marco Candela; Silvia Turroni; Erwin G Zoetendal; Gerben D A Hermes; Caumon Elodie; Nathalie Meunier; Corinne Malpuech Brugere; Estelle Pujos-Guillot; Agnes M Berendsen; Lisette C P G M De Groot; Edith J M Feskins; Joanna Kaluza; Barbara Pietruszka; Marta Jeruszka Bielak;

    Objective Ageing is accompanied by deterioration of multiple bodily functions and inflammation, which collectively contribute to frailty. We and others have shown that frailty co-varies with alterations in the gut microbiota in a manner accelerated by consumption of a restricted diversity diet. The Mediterranean diet (MedDiet) is associated with health. In the NU-AGE project, we investigated if a 1

    更新日期:2020-02-18
  • Advances in non-invasive assessment of hepatic fibrosis
    Gut (IF 17.943) Pub Date : 2020-02-17
    Rohit Loomba; Leon A Adams

    Liver fibrosis should be assessed in all individuals with chronic liver disease as it predicts the risk of future liver-related morbidity and thus need for treatment, monitoring and surveillance. Non-invasive fibrosis tests (NITs) overcome many limitations of liver biopsy and are now routinely incorporated into specialist clinical practice. Simple serum-based tests (eg, Fibrosis Score 4, non-alcoholic

    更新日期:2020-02-17
  • Small intestinal bacterial overgrowth (SIBO) as a potential cause of impaired spermatogenesis
    Gut (IF 17.943) Pub Date : 2020-02-17
    Kelton Tremellen; Karma Pearce

    We commend Ding and colleagues for their innovative work investigating how high-fat diet-induced changes to the gut microbiome can alter spermatogenesis.1 This link between the gut microbiome and testicular function had earlier been suggested by studies that reported the consumption of probiotic bacteria could improve spermatogenesis and testosterone production in both mice and men.2 3 Furthermore,

    更新日期:2020-02-17
  • Lumen-apposing metal stent placement for drainage of pancreatic fluid collections: predictors of adverse events
    Gut (IF 17.943) Pub Date : 2020-02-17
    Ji Young Bang; Robert H Hawes; Shyam Varadarajulu

    Although rare in occurrence, adverse events such as delayed bleeding and buried stent syndrome have been reported after lumen-apposing metal stents (LAMS) placement in patients undergoing endoscopic ultrasound (EUS)-guided drainage of pancreatic fluid collections (PFCs). In a prospective study, we observed delayed adverse events in 6.4% of 188 patients which occurred when the PFCs were 7 cm or smaller

    更新日期:2020-02-17
  • Liver tissue microbiome in NAFLD: next step in understanding the gut–liver axis?
    Gut (IF 17.943) Pub Date : 2020-02-14
    Herbert Tilg; Remy Burcelin; Valentina Tremaroli

    The pathogenesis of non-alcoholic fatty liver disease (NAFLD), the most common global liver disease, is complex as multiple parallel hits drive this disorder. Whereas lipotoxicity, insulin resistance, inflammatory processes, oxidative stress and others reflect key components, studies from the past years have clearly shown that the gut microbiome might also substantially contribute to the evolution

    更新日期:2020-02-14
  • Hepatitis D virus: is it all in the family?
    Gut (IF 17.943) Pub Date : 2020-02-14
    Anders Boyd; Gilles Wandeler

    Hepatitis delta virus (HDV) infection is the most severe form of chronic viral hepatitis: HDV-infected individuals are more likely to die from advanced liver disease compared with hepatitis B virus (HBV)-infected without HDV and their risk of developing hepatocellular carcinoma is up to nine times higher.1 HDV is a defective virus, using the HBV surface antigen to enter hepatocytes. Pegylated interferon-alfa

    更新日期:2020-02-14
  • Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study
    Gut (IF 17.943) Pub Date : 2020-02-14
    Rachael Stolzenberg-Solomon; Andriy Derkach; Steven Moore; Stephanie J Weinstein; Demetrius Albanes; Joshua Sampson

    Objective To assess whether prediagnostic metabolites were associated with incident pancreatic ductal adenocarcinoma (PDAC) in a prospective cohort study. Design We conducted an untargeted analysis of 554 known metabolites measured in prediagnostic serum (up to 24 years) to determine their association with incident PDAC in a nested case-control study of male smokers (372 matched case-control sets)

    更新日期:2020-02-14
  • Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity
    Gut (IF 17.943) Pub Date : 2020-02-14
    Maria Raffaella Barbaro; Cesare Cremon; Antonio Maria Morselli-Labate; Antonio Di Sabatino; Paolo Giuffrida; Gino Roberto Corazza; Michele Di Stefano; Giacomo Caio; Giovanni Latella; Carolina Ciacci; Daniele Fuschi; Marianna Mastroroberto; Lara Bellacosa; Vincenzo Stanghellini; Umberto Volta; Giovanni Barbara

    Objective Non-coeliac gluten sensitivity (NCGS) is characterised by intestinal and extraintestinal symptoms related to the ingestion of gluten-containing foods, in the absence of coeliac disease (CD) and wheat allergy. No biomarkers are available to diagnose NCGS and the gold standard double-blind placebo-controlled gluten challenge is clinically impractical. The aim of our work was to investigate

    更新日期:2020-02-14
  • Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure
    Gut (IF 17.943) Pub Date : 2020-02-12
    Loris Pironi; Ezra Steiger; Francisca Joly; Geert J A Wanten; Cecile Chambrier; Umberto Aimasso; Anna Simona Sasdelli; Kinga Szczepanek; Amelia Jukes; Miriam Theilla; Marek Kunecki; Joanne Daniels; Mireille J Serlie; Sheldon C Cooper; Florian Poullenot; Henrik Højgaard Rasmussen; Charlene W Compher; Adriana Crivelli; Sarah-Jane Hughes; Lidia Santarpia; Francesco William Guglielmi; Nada Rotovnik Kozjek

    Background and aim No marker to categorise the severity of chronic intestinal failure (CIF) has been developed. A 1-year international survey was carried out to investigate whether the European Society for Clinical Nutrition and Metabolism clinical classification of CIF, based on the type and volume of the intravenous supplementation (IVS), could be an indicator of CIF severity. Methods At baseline

    更新日期:2020-02-12
  • Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor
    Gut (IF 17.943) Pub Date : 2020-02-12
    Yun Kit Yeoh; Zigui Chen; Martin C S Wong; Mamie Hui; Jun Yu; Siew C Ng; Joseph J Y Sung; Francis K L Chan; Paul K S Chan

    Objective Fusobacteria are not common nor relatively abundant in non-colorectal cancer (CRC) populations, however, we identified multiple Fusobacterium taxa nearly absent in western and rural populations to be comparatively more prevalent and relatively abundant in southern Chinese populations. We investigated whether these represented known or novel lineages in the Fusobacterium genus, and assessed

    更新日期:2020-02-12
  • Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori
    Gut (IF 17.943) Pub Date : 2020-02-12
    Takahisa Furuta; Mihoko Yamade; Takuma Kagami; Takahiro Suzuki; Tomohiro Higuchi; Shinya Tani; Yasushi Hamaya; Moriya Iwaizumi; Hiroaki Miyajima; Kazuo Umemura; Satoshi Osawa; Ken Sugimoto

    We read the manuscript written by Suzuki et al 1 with interest. They reported that the eradication rate of Helicobacter pylori attained by the dual therapy with vonoprazan and amoxicillin (VA-Dual) was almost the same as that attained by the triple therapy with vonoprazan, amoxicillin and clarithromycin (VAC-Triple), as previously reported by us.2 The most interesting point in this paper was that the

    更新日期:2020-02-12
  • Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma
    Gut (IF 17.943) Pub Date : 2020-02-12
    Enrico N De Toni; Daniel Roessler

    We have read with interest the paper by Gerbes et al ,1 which highlights the current developments in the treatment of hepatocellular carcinoma (HCC). Fibrolamellar HCC (FL-HCC) is, in contrast to HCC,2 an infrequent tumour, most often occurring in adolescents or young adults without underlying liver disease.3 Chemotherapy-based regimens are typically used to treat FL-HCC based on studies in small patients

    更新日期:2020-02-12
  • Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?
    Gut (IF 17.943) Pub Date : 2020-02-12
    Pedro Marcos; Gisela Brito-Gonçalves; Diogo Libânio; Inês Pita; Rui Castro; Inês Sá; Mário Dinis-Ribeiro; Pedro Pimentel-Nunes

    Objectives To assess the value of endoscopic grading of gastric intestinal metaplasia (EGGIM), operative link on gastritis assessment (OLGA) and operative link on gastric intestinal metaplasia (OLGIM) on risk stratification for early gastric neoplasia (EGN) and to investigate other factors possibly associated with its development. Design Single centre, case–control study including 187 patients with

    更新日期:2020-02-12
  • Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice
    Gut (IF 17.943) Pub Date : 2020-02-11
    Craig Haifer; Colleen R Kelly; Sudarshan Paramsothy; David Andresen; Lito E Papanicolas; Genevieve L McKew; Thomas J Borody; Michael Kamm; Samuel P Costello; Jane M Andrews; Jakob Begun; Hiu Tat Chan; Susan Connor; Simon Ghaly; Paul DR Johnson; Daniel A Lemberg; Ramesh Paramsothy; Andrew Redmond; Harsha Sheorey; David van der Poorten; Rupert W Leong

    Objective Faecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production

    更新日期:2020-02-11
  • Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients
    Gut (IF 17.943) Pub Date : 2020-02-10
    Julie Rodriguez; Sophie Hiel; Audrey M Neyrinck; Tiphaine Le Roy; Sarah A Pötgens; Quentin Leyrolle; Barbara D Pachikian; Marco A Gianfrancesco; Patrice D Cani; Nicolas Paquot; Miriam Cnop; Nicolas Lanthier; Jean-Paul Thissen; Laure B Bindels; Nathalie M Delzenne

    Objective The gut microbiota has been proposed as an interesting therapeutic target for metabolic disorders. Inulin as a prebiotic has been shown to lessen obesity and related diseases. The aim of the current study was to investigate whether preintervention gut microbiota characteristics determine the physiological response to inulin. Design The stools from four obese donors differing by microbial

    更新日期:2020-02-10
  • Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B
    Gut (IF 17.943) Pub Date : 2020-02-10
    Faisal Kamal; Muhammad Ali Khan; Aijaz Ahmed; Satheesh Nair

    We read with interest the study by Lee et al 1 showing no difference in risk of hepatocellular carcinoma (HCC) and mortality or liver transplantation (LT) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV). We searched Medline, Embase, Scopus, Web of Science and Cochrane database to identify studies comparing TDF and ETV for prevention of HCC

    更新日期:2020-02-10
  • Personalised screening for colorectal cancer, ready for take-off
    Gut (IF 17.943) Pub Date : 2020-03-01
    Ernst J Kuipers; Esmée J Grobbee

    Colorectal cancer (CRC) is among the most common causes of cancer-related mortality.1 For the purpose of population-based CRC screening, faecal immunochemical tests (FIT) have been widely accepted.2 FIT can both be used in a qualitative manner, leading to either a positive or negative result, or a quantitative manner resulting in the reporting of microgram faecal haemoglobin (Hb) per gram faeces. Screenees

    更新日期:2020-02-07
  • Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles
    Gut (IF 17.943) Pub Date : 2020-03-01
    Adam Enver Frampton; Elisa Giovannetti

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm because of difficulties in early detection. This delay is caused by lack of non-invasive screening, or tests for early diagnosis, in addition to rapid disease progression with non-specific symptoms. Most patients present with unresectable disease, and outcomes are consequently poor. Furthermore, advances in surgical techniques, perioperative

    更新日期:2020-02-07
  • Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer
    Gut (IF 17.943) Pub Date : 2020-03-01
    Jolien J J Tjalma; Marjory Koller; Matthijs D Linssen; Elmire Hartmans; Steven de Jongh; Annelies Jorritsma-Smit; Arend Karrenbeld; Elisabeth G de Vries; Jan H Kleibeuker; Jan Pieter Pennings; Klaas Havenga; Patrick HJH Hemmer; Geke AP Hospers; Boudewijn van Etten; Vasilis Ntziachristos; Gooitzen M van Dam; Dominic J Robinson; Wouter B Nagengast

    Quantitative fluorescence endoscopy (QFE) is a new technique that can visualise and quantify fluorescently tagged tumour tissue. In 25 patients with locally advanced rectal cancer (LARC), we evaluated QFE targeting vascular endothelial growth factor A (VEGFA) to detect residual tumour after neoadjuvant chemoradiotherapy (nCRT). QFE detected significantly higher fluorescence in tumour compared with

    更新日期:2020-02-07
  • Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG)
    Gut (IF 17.943) Pub Date : 2020-03-01
    Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill

    Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost 30% of the population in the UK have a family history of CRC. The quantification of an individual’s lifetime risk of gastrointestinal cancer may incorporate clinical and molecular data, and depends on accurate phenotypic assessment and genetic diagnosis. In turn this may facilitate targeted risk-reducing interventions

    更新日期:2020-02-07
  • Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study
    Gut (IF 17.943) Pub Date : 2020-03-01
    Chuan-Guo Guo; Ka Shing Cheung; Feifei Zhang; Esther W Chan; Lijia Chen; Ian CK Wong; Wai K Leung

    Objective The risk of GI bleeding (GIB) in aspirin users after Helicobacter pylori (HP) eradication remains poorly defined. We characterised the incidences and temporal trends of hospitalisations for all GIB in aspirin users after HP eradication therapy. Design Based on a territory-wide health database, we identified all patients who had received the first course of clarithromycin-based triple therapy

    更新日期:2020-02-07
  • Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014
    Gut (IF 17.943) Pub Date : 2020-03-01
    Ola Olén; Johan Askling; Michael C Sachs; Martin Neovius; Karin E Smedby; Anders Ekbom; Jonas F Ludvigsson

    Objectives To examine all-cause and cause-specific mortality in adult-onset and elderly-onset IBD and to describe time trends in mortality over the past 50 years. Design Swedish nationwide register-based cohort study 1964–2014, comparing mortality in 82 718 incident IBD cases (inpatient and non-primary outpatient care) with 10 times as many matched general population reference individuals (n=801 180

    更新日期:2020-02-07
  • Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn’s disease
    Gut (IF 17.943) Pub Date : 2020-03-01
    Harry Sokol; Loic Brot; Carmen Stefanescu; Claire Auzolle; Nicolas Barnich; Anthony Buisson; Mathurin Fumery; Benjamin Pariente; Lionel Le Bourhis; Xavier Treton; Stéphane Nancey; Matthieu Allez; Philippe Seksik

    Objective Following ileal resection for Crohn’s disease (CD), recurrence is very frequent. Although several clinical risk factors of recurrence have been identified, predicting relapse remains challenging. Performing an ileocolonoscopy within the first year after surgery is currently recommended to assess endoscopic recurrence and to adjust the treatment. We took advantage of a large prospective multicentric

    更新日期:2020-02-07
  • Modulation of cytokine patterns and microbiome during pregnancy in IBD
    Gut (IF 17.943) Pub Date : 2020-03-01
    Janine van der Giessen; Dana Binyamin; Anna Belogolovski; Sigal Frishman; Kinneret Tenenbaum-Gavish; Eran Hadar; Yoram Louzoun; Maikel Petrus Peppelenbosch; Christien Janneke van der Woude; Omry Koren; Gwenny Manel Fuhler

    Objective Pregnancy may affect the disease course of IBD. Both pregnancy and IBD are associated with altered immunology and intestinal microbiology. However, to what extent immunological and microbial profiles are affected by pregnancy in patients with IBD remains unclear. Design Faecal and serum samples were collected from 46 IBD patients (31 Crohn’s disease (CD) and 15 UC) and 179 healthy controls

    更新日期:2020-02-07
  • Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay
    Gut (IF 17.943) Pub Date : 2020-03-01
    Cécile Vors; Laurie Joumard-Cubizolles; Manon Lecomte; Emmanuel Combe; Lemlih Ouchchane; Jocelyne Drai; Ketsia Raynal; Florent Joffre; Laure Meiller; Mélanie Le Barz; Patrice Gaborit; Aurélie Caille; Monique Sothier; Carla Domingues-Faria; Adeline Blot; Aurélie Wauquier; Emilie Blond; Valérie Sauvinet; Geneviève Gésan-Guiziou; Jean-Pierre Bodin; Philippe Moulin; David Cheillan; Hubert Vidal; Béatrice

    Objective To investigate whether milk polar lipids (PL) impact human intestinal lipid absorption, metabolism, microbiota and associated markers of cardiometabolic health. Design A double-blind, randomised controlled 4-week study involving 58 postmenopausal women was used to assess the chronic effects of milk PL consumption (0, 3 or 5 g-PL/day) on lipid metabolism and gut microbiota. The acute effects

    更新日期:2020-02-07
  • Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time
    Gut (IF 17.943) Pub Date : 2020-03-01
    Pieter de Groot; Torsten Scheithauer; Guido J Bakker; Andrei Prodan; Evgeni Levin; Muhammad Tanweer Khan; Hilde Herrema; Mariette Ackermans; Mireille J M Serlie; Maurits de Brauw; Johannes H M Levels; Amber Sales; Victor E Gerdes; Marcus Ståhlman; Alinda W M Schimmel; Geesje Dallinga-Thie; Jacques JGHM Bergman; Frits Holleman; Joost B L Hoekstra; Albert Groen; Fredrik Bäckhed; Max Nieuwdorp

    Objective Bariatric surgery improves glucose metabolism. Recent data suggest that faecal microbiota transplantation (FMT) using faeces from postbariatric surgery diet-induced obese mice in germ-free mice improves glucose metabolism and intestinal homeostasis. We here investigated whether allogenic FMT using faeces from post-Roux-en-Y gastric bypass donors (RYGB-D) compared with using faeces from metabolic

    更新日期:2020-02-07
  • Gut dysbiosis induces the development of pre-eclampsia through bacterial translocation
    Gut (IF 17.943) Pub Date : 2020-03-01
    Xia Chen; Pan Li; Mian Liu; Huimin Zheng; Yan He; Mu-Xuan Chen; Wenli Tang; Xiaojing Yue; Yongxin Huang; Lingling Zhuang; Zhijian Wang; Mei Zhong; Guibao Ke; Haoyue Hu; Yinglin Feng; Yun Chen; Yanhong Yu; Hongwei Zhou; Liping Huang

    Objective Pre-eclampsia (PE) is one of the malignant metabolic diseases that complicate pregnancy. Gut dysbiosis has been identified for causing metabolic diseases, but the role of gut microbiome in the pathogenesis of PE remains unknown. Design We performed a case–control study to compare the faecal microbiome of PE and normotensive pregnant women by 16S ribosomal RNA (rRNA) sequencing. To address

    更新日期:2020-02-07
  • Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy
    Gut (IF 17.943) Pub Date : 2020-03-01
    Carlo Senore; Marco Zappa; Cinzia Campari; Sergio Crotta; Paola Armaroli; Arrigo Arrigoni; Paola Cassoni; Rossana Colla; Mario Fracchia; Fabrizio Gili; Grazia Grazzini; Roberto Lolli; Patrizia Menozzi; Lorenzo Orione; Salvatore Polizzi; Stefano Rapi; Emilia Riggi; Tiziana Rubeca; Romano Sassatelli; Carmen Visioli; Nereo Segnan

    Objective To estimate the predictive role of faecal haemoglobin (f-Hb) concentration among subjects with faecal immunochemical test (FIT) results below the positivity cut-off for the subsequent risk of advanced neoplasia (AN: colorectal cancer—CRC—or advanced adenoma). Design Prospective cohort of subjects aged 50–69 years, undergoing their first FIT between 1 January 2004 and 31 December 2010 in four

    更新日期:2020-02-07
  • Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
    Gut (IF 17.943) Pub Date : 2020-03-01
    Anthony Dohan; Benoit Gallix; Boris Guiu; Karine Le Malicot; Caroline Reinhold; Philippe Soyer; Jaafar Bennouna; Francois Ghiringhelli; Emilie Barbier; Valérie Boige; Julien Taieb; Olivier Bouché; Eric François; Jean-Marc Phelip; Christian Borel; Roger Faroux; Jean-Francois Seitz; Stéphane Jacquot; Meher Ben Abdelghani; Faiza Khemissa-Akouz; Dominique Genet; Jean Louis Jouve; Yves Rinaldi; Françoise

    Purpose The objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders. Methods This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal

    更新日期:2020-02-07
  • Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma
    Gut (IF 17.943) Pub Date : 2020-03-01
    Shulin Yu; Yuchen Li; Zhuan Liao; Zheng Wang; Zhen Wang; Yan Li; Ling Qian; Jingjing Zhao; Huajie Zong; Bin Kang; Wen-Bin Zou; Kun Chen; Xianghuo He; Zhiqiang Meng; Zhen Chen; Shenglin Huang; Peng Wang

    Objective Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose at resectable stage. Recent studies have suggested that extracellular vesicles (EVs) contain long RNAs. The aim of this study was to develop a diagnostic (d-)signature for the detection of PDAC based on EV long RNA (exLR) profiling. Design We conducted a case-control study with 501 participants, including 284 patients with PDAC

    更新日期:2020-02-07
  • Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis
    Gut (IF 17.943) Pub Date : 2020-03-01
    Oliver Krenkel; Jana Hundertmark; Ali T Abdallah; Marlene Kohlhepp; Tobias Puengel; Tilmann Roth; Diogo Philippini Pontual Branco; Jana C Mossanen; Tom Luedde; Christian Trautwein; Ivan G Costa; Frank Tacke

    Objective Bone marrow-derived myeloid cells accumulate in the liver as monocytes and macrophages during the progression of obesity-related non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH). Myeloid cells comprise heterogeneous subsets, and dietary overnutrition may affect macrophages in the liver and bone marrow. We therefore aimed at characterising in depth the functional adaptations

    更新日期:2020-02-07
  • Epidemiology of chronic liver diseases in the USA in the past three decades
    Gut (IF 17.943) Pub Date : 2020-03-01
    Zobair M Younossi; Maria Stepanova; Youssef Younossi; Pegah Golabi; Alita Mishra; Nila Rafiq; Linda Henry

    Objective Given significant advances in treatment of viral hepatitis and the growing epidemic of obesity, the burden of the different types of liver diseases in the USA may be changing. Our aim was to assess the shift in the prevalence of different liver disease aetiologies in the USA over the past three decades. Design National Health and Nutrition Examination Surveys (NHANES; cross-sectional 1988

    更新日期:2020-02-07
  • Alterations of gut microbiome in autoimmune hepatitis
    Gut (IF 17.943) Pub Date : 2020-03-01
    Yiran Wei; Yanmei Li; Li Yan; Chunyan Sun; Qi Miao; Qixia Wang; Xiao Xiao; Min Lian; Bo Li; Yong Chen; Jun Zhang; You Li; Bingyuan Huang; Yikang Li; Qin Cao; Zhuping Fan; Xiaoyu Chen; Jing-Yuan Fang; Merrill Eric Gershwin; Ruqi Tang; Xiong Ma

    Objective The significance of the liver-microbiome axis has been increasingly recognised as a major modulator of autoimmunity. The aim of this study was to take advantage of a large well-defined corticosteroids treatment-naïve group of patients with autoimmune hepatitis (AIH) to rigorously characterise gut dysbiosis compared with healthy controls. Design We performed a cross-sectional study of individuals

    更新日期:2020-02-07
  • Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells
    Gut (IF 17.943) Pub Date : 2020-03-01
    Nick Powell; Eirini Pantazi; Polychronis Pavlidis; Anastasia Tsakmaki; Katherine Li; Feifei Yang; Aimee Parker; Carmen Pin; Domenico Cozzetto; Danielle Minns; Emilie Stolarczyk; Svetlana Saveljeva; Rami Mohamed; Paul Lavender; Behdad Afzali; Jonathan Digby-Bell; Tsui Tjir-Li; Arthur Kaser; Joshua Friedman; Thomas T MacDonald; Gavin A Bewick; Graham M Lord

    Objective The functional role of interleukin-22 (IL22) in chronic inflammation is controversial, and mechanistic insights into how it regulates target tissue are lacking. In this study, we evaluated the functional role of IL22 in chronic colitis and probed mechanisms of IL22-mediated regulation of colonic epithelial cells. Design To investigate the functional role of IL22 in chronic colitis and how

    更新日期:2020-02-07
  • Novel concepts in the pathophysiology and treatment of functional dyspepsia
    Gut (IF 17.943) Pub Date : 2020-03-01
    Lucas Wauters; Nicholas J Talley; Marjorie M Walker; Jan Tack; Tim Vanuytsel

    Emerging data increasingly point towards the duodenum as a key region underlying the pathophysiology of functional dyspepsia (FD), one of the most prevalent functional GI disorders. The duodenum plays a major role in the control and coordination of gastroduodenal function. Impaired duodenal mucosal integrity and low-grade inflammation have been associated with altered neuronal signalling and systemic

    更新日期:2020-02-07
  • GI highlights from the literature
    Gut (IF 17.943) Pub Date : 2020-03-01
    Mairi H McLean

    ### Virome signatures in IBD Clooney AG, Sutton TDS, Shkoporov AN, et al . Whole-virome analysis sheds light on viral dark matter in IBD. Cell Host Microbe 2019;26:1–15. Analysing whole virome signatures within the human gut is the next major step in the field of the gut microbiome. To date, most virome analyses have detailed only a limited fraction of known viruses. However, it is estimated that the

    更新日期:2020-02-07
  • Duration of organ failure impacts mortality in acute pancreatitis
    Gut (IF 17.943) Pub Date : 2020-03-01
    Na Shi; Tingting Liu; Daniel de la Iglesia-Garcia; Lihui Deng; Tao Jin; Lan Lan; Ping Zhu; Weiming Hu; Zongguang Zhou; Vikesh Singh; J Enrique Dominguez-Munoz; John Windsor; Wei Huang; Qing Xia; Robert Sutton

    We read with great interest the recent Gut publication by Schepers et al 1 reporting no association between the time of onset or duration of persistent organ failure (POF, >48 hours, distinguished from transient organ failure <48 hours) and mortality in a subset of patients (240/639) with acute pancreatitis (AP). Previously it has been proposed that there are two peaks of POF and mortality in patients

    更新日期:2020-02-07
  • Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
    Gut (IF 17.943) Pub Date : 2020-03-01
    Yutaka Yamaji; Yoshihiro Hirata

    We read with interest the report by Doorakkers et al describing the effect of Helicobacter pylori eradication in preventing the development of non-cardia gastric adenocarcinoma in a population-based Swedish cohort.1 The authors used nationwide Swedish registries to investigate the incidence of gastric adenocarcinoma after H. pylori eradication treatment. Specifically, standardised incidence ratios

    更新日期:2020-02-07
  • Changing trends in coding for depression among the UK inflammatory bowel disease population
    Gut (IF 17.943) Pub Date : 2020-03-01
    Jonathan Blackwell; Sonia Saxena; Richard C Pollok

    We read with interest the findings of Frolkis et al and welcome the contribution to this challenging field of research.1 An important consideration in the methodology used is the case definition of incident depression, defined as any patient with a code for a depressive disorder in The Health Improvement Network (THIN) database between 1986 and 2012. The authors acknowledge …

    更新日期:2020-02-07
  • Changing trends in coding for depression among the UK IBD population: reply from authors
    Gut (IF 17.943) Pub Date : 2020-03-01
    Isabelle Vallerand; Alexandra D Frolkis; Scott Patten; Gilaad G Kaplan

    We thank Blackwell et al 1 for raising an important question about the classification of depression in a population of IBD patients in the UK. In our study,examining depression as a risk factor for the development of IBD,2 we chose to use a more restrictive case definition of depression based closely on a definition of major depressive disorder (MDD) as a clinically significant form of depression recognised

    更新日期:2020-02-07
  • Case of IgG4-associated sclerosing cholangitis with normal serum IgG4 concentration, diagnosed by anti-laminin 511-E8 antibody: a novel autoantibody in patients with autoimmune pancreatitis
    Gut (IF 17.943) Pub Date : 2020-03-01
    Yukari Kato; Keishiro Azuma; Hitoshi Someda; Masahiro Shiokawa; Tsutomu Chiba

    We read with great interest the article by Hubers et al published in Gut .1 They identified annexin A11 as an autoantigen in IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP), which is targeted by IgG4 and IgG1 antibodies in the sera of IAC/AIP patients.1 Notably, they reported that none of the 20 patients tested for primary sclerosing cholangitis (PSC) had anti-annexin A11 antibodies

    更新日期:2020-02-07
  • Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?
    Gut (IF 17.943) Pub Date : 2020-03-01
    Calum D Moulton; Christine Norton; Nick Powell; Zahra Mohamedali; Christopher W P Hopkins

    We read with interest Frolkis and colleagues’ recent study, in which depression was associated with increased risk of incident IBD in a large primary care database.1 While treatment of depression in IBD has been suggested to improve IBD outcomes,2 this study goes further, suggesting that assertive pharmacological treatment of depression could reduce the incidence of IBD altogether. Despite the study

    更新日期:2020-02-07
  • Response to the letter: Identification of trimethylamine N-oxide (TMAO)-producer phenotype is interesting, but is it helpful?
    Gut (IF 17.943) Pub Date : 2020-03-01
    Wei-Kai Wu; Lee-Yan Sheen; Ming-Shiang Wu

    We thank Arduini et al 1 for the feedback. The importance of identifying trimethylanine N-oxide (TMAO)-producer phenotype was challenged in doubt about the significance of TMAO in cardiovascular disease (CVD).1 2 The reason we regard TMAO as a potential harmful rather than a beneficial or bystander molecule for CVD is based on a careful literature review from both affirmative and negative sides.3 4

    更新日期:2020-02-07
  • Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
    Gut (IF 17.943) Pub Date : 2020-03-01
    Alexandra D Frolkis; Isabelle A Vallerand; Scott B Patten; Gilaad G Kaplan

    We appreciate the thoughtful feedback and points raised by authors Moulton, Norton, Powell, Mohamedali and Hopkins regarding the temporality between depression and inflammatory bowel disease (IBD) diagnosis and recommendation to perform further sensitivity analyses.1 The authors correctly highlight that the prodromal effects of IBD, including fatigue and low mood, prior to diagnosis may mimic depression

    更新日期:2020-02-07
  • IIc or not IIc: a question for meticulous optical evaluation
    Gut (IF 17.943) Pub Date : 2020-03-01
    Neal Shahidi; Mayenaaz Sidhu; Iddo Bar-Yishay; Michael J Bourke

    A middle-aged man was referred to assess the feasibility of endoscopic removal of a 35 mm laterally spreading lesion within the sigmoid colon. The referring endoscopist appreciated a central depression (0–IIc Paris morphology) and raised the concern for submucosal invasive cancer. Using an Olympus 190 series high-definition colonoscope (Olympus, Tokyo, Japan), the lesion was carefully examined under

    更新日期:2020-02-07
  • Correction: Signally via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury
    Gut (IF 17.943) Pub Date : 2020-03-01
    BMJ Publishing Group Ltd and British Society of Gastroenterology

    Arriazu E, Ge X, Leung T-M, et al . Signally via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut 2017;66:1123–37. doi: 10.1136/gutjnl-2015-310752. Panel B in figure 6 is incorrect and has been removed. The updated figure and legend should be: Figure 6 rOPN activates NOX and inhibits HDACs1/2 promoting HMGB1 acetylation and translocation along with

    更新日期:2020-02-07
  • Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer
    Gut (IF 17.943) Pub Date : 2020-02-07
    Martin Pichler; Cristian Rodriguez-Aguayo; Su Youn Nam; Mihnea Paul Dragomir; Recep Bayraktar; Simone Anfossi; Erik Knutsen; Cristina Ivan; Enrique Fuentes-Mattei; Sang Kil Lee; Hui Ling; Tina Catela Ivkovic; Guoliang Huang; Li Huang; Yoshinaga Okugawa; Hiroyuki Katayama; Ayumu Taguchi; Emine Bayraktar; Rajat Bhattacharya; Paola Amero; William Ruixian He; Anh M Tran; Petra Vychytilova-Faltejskova;

    Objective To investigate the function of a novel primate-specific long non-coding RNA (lncRNA), named FLANC, based on its genomic location (co-localised with a pyknon motif), and to characterise its potential as a biomarker and therapeutic target. Design FLANC expression was analysed in 349 tumours from four cohorts and correlated to clinical data. In a series of multiple in vitro and in vivo models

    更新日期:2020-02-07
  • Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility
    Gut (IF 17.943) Pub Date : 2020-02-07
    Mihnea Paul Dragomir; Scott Kopetz; Jaffer A Ajani; George Adrian Calin

    One of the most unexpected discoveries in molecular oncology, in the last decades, was the identification of a new layer of protein coding gene regulation by transcripts that do not codify for proteins, the non-coding RNAs. These represent a heterogeneous category of transcripts that interact with many types of genetic elements, including regulatory DNAs, coding and other non-coding transcripts and

    更新日期:2020-02-07
  • Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
    Gut (IF 17.943) Pub Date : 2020-01-30
    Guido Alessandro Baselli; Paola Dongiovanni; Raffaela Rametta; Marica Meroni; Serena Pelusi; Marco Maggioni; Sara Badiali; Piero Pingitore; Samantha Maurotti; Tiziana Montalcini; Alice Emma Taliento; Daniele Prati; Giorgio Rossi; Anna Ludovica Fracanzani; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti

    Objective Efforts to manage non-alcoholic fatty liver disease (NAFLD) are limited by the incomplete understanding of the pathogenic mechanisms and the absence of accurate non-invasive biomarkers. The aim of this study was to identify novel NAFLD therapeutic targets andbiomarkers by conducting liver transcriptomic analysis in patients stratified by the presence of the PNPLA3 I148M genetic risk variant

    更新日期:2020-01-31
  • Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035
    Gut (IF 17.943) Pub Date : 2020-01-30
    Melina Arnold; Jin Young Park; M Constanza Camargo; Nuno Lunet; David Forman; Isabelle Soerjomataram

    Objectives The incidence of gastric cancer continues to decrease globally, approaching levels that in some populations could define it as a rare disease. To explore this on a wider scale, we predict its future burden in 34 countries with long-standing population-based data. Methods Data on gastric cancer incidence by year of diagnosis, sex and age were extracted for 92 cancer registries in 34 countries

    更新日期:2020-01-31
  • Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease
    Gut (IF 17.943) Pub Date : 2020-01-30
    Grace Elizabeth Dolman; Patrick T F Kennedy

    We would like to congratulate Lamb et al for the production of such a comprehensive guideline for the management of inflammatory bowel disease (IBD).1 Further clarification is warranted regarding screening for hepatitis B virus (HBV) prior to immunosuppression and subsequent management to reduce the risk of virus reactivation. The guidelines recommend screening for HBV at diagnosis and before immunomodulatory

    更新日期:2020-01-31
  • SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
    Gut (IF 17.943) Pub Date : 2020-01-30
    Alexander Biederstädt; Zonera Hassan; Christian Schneeweis; Markus Schick; Lara Schneider; Alexander Muckenhuber; Yingfen Hong; Gerrit Siegers; Lisa Nilsson; Matthias Wirth; Zahra Dantes; Katja Steiger; Kathrin Schunck; Steve Langston; H-P Lenhof; Andrea Coluccio; Felix Orben; Jolanta Slawska; Anna Scherger; Dieter Saur; Stefan Müller; Roland Rad; Wilko Weichert; Jonas Nilsson; Maximilian Reichert;

    Objective Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumour biology

    更新日期:2020-01-31
Contents have been reproduced by permission of the publishers.
导出
全部期刊列表>>
Springer Nature 2019高下载量文章和章节
化学/材料学中国作者研究精选
《科学报告》最新环境科学研究
ACS材料视界
自然科研论文编辑服务
中南大学国家杰青杨华明
南开大学陈弓课题组招聘启事
中南大学
材料化学和生物传感方向博士后招聘
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug